Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 3
2010 3
2011 6
2012 11
2013 7
2014 5
2015 7
2016 6
2017 12
2018 7
2019 9
2020 4
2021 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, Krause T, Schweitzer A, Schnoy E, Atreya R, Teich N, Trentmann L, Ehehalt R, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: di giuseppe r. Inflamm Bowel Dis. 2023 Jul 31:izad138. doi: 10.1093/ibd/izad138. Online ahead of print. Inflamm Bowel Dis. 2023. PMID: 37523666
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Krause T, Hoffstadt M, Ehehalt R, Trentmann L, Schweitzer A, Jessen P, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: di giuseppe r. Aliment Pharmacol Ther. 2023 Aug;58(4):429-442. doi: 10.1111/apt.17616. Epub 2023 Jun 15. Aliment Pharmacol Ther. 2023. PMID: 37322825
Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Helwig U, Teich N, Schmidt C, Hartmann P, Sobotzki C, Schreiber S. Bokemeyer B, et al. Among authors: di giuseppe r. Aliment Pharmacol Ther. 2023 Jul;58(1):35-47. doi: 10.1111/apt.17512. Epub 2023 Apr 13. Aliment Pharmacol Ther. 2023. PMID: 37051808
Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Mohl W, Teich N, Hoffstadt M, Schweitzer A, von der Ohe M, Gauss A, Atreya R, Krause T, Blumenstein I, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: di giuseppe r. Inflamm Bowel Dis. 2023 Nov 2;29(11):1741-1750. doi: 10.1093/ibd/izac271. Inflamm Bowel Dis. 2023. PMID: 36633301
Blood Metabolomic Profiling Confirms and Identifies Biomarkers of Food Intake.
Langenau J, Oluwagbemigun K, Brachem C, Lieb W, Giuseppe RD, Artati A, Kastenmüller G, Weinhold L, Schmid M, Nöthlings U. Langenau J, et al. Among authors: giuseppe rd. Metabolites. 2020 Nov 17;10(11):468. doi: 10.3390/metabo10110468. Metabolites. 2020. PMID: 33212857 Free PMC article.
70 results